{
  "docId": "019de073-d0ca-7288-9ab4-c51009336f37",
  "docSlug": "2ef2fad38453444b0a07cd5e908bf527",
  "documentTitle": "PaxMedica | Investor Presentation Deck | 24 slides",
  "authorId": "paxmedica",
  "authorName": "PaxMedica",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 3,
  "pageCount": 24,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-d0ca-7288-9ab4-c51009336f37/3",
  "deckHref": "/decks/019de073-d0ca-7288-9ab4-c51009336f37",
  "deckJsonHref": "/decks/019de073-d0ca-7288-9ab4-c51009336f37.json",
  "deckAnchorHref": "/decks/019de073-d0ca-7288-9ab4-c51009336f37#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.045,
        "w": 0.125,
        "x": 0.858,
        "y": 0.018
      },
      "kind": "image",
      "text": "PAXMEDICA",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96f3d610-874c-4aa1-8463-ddc2a5695137",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.132,
        "w": 0.846,
        "x": 0.077,
        "y": 0.385
      },
      "kind": "paragraph",
      "text": "PAX-101, an intravenous formulation of suramin, has been historically used as a life-saving drug to treat a rare and fatal tropical disease, Human African Trypanosomiasis (\"HAT\"). PaxMedica will first seek accelerated approval for PAX-101 for the treatment of HAT under the US Rare Tropical Disease Priority Review Voucher program to gain valuable program incentives.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19d6bc64-c34e-4c74-9ffa-d8298ab1defe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.044,
        "w": 0.846,
        "x": 0.077,
        "y": 0.538
      },
      "kind": "paragraph",
      "text": "A global multi-centered clinical trial of PAX-101 in ASD will then commence following US IND approval.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6cca9925-8c9e-4ced-b813-2923a2b29762",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.088,
        "w": 0.846,
        "x": 0.077,
        "y": 0.273
      },
      "kind": "paragraph",
      "text": "PaxMedica is a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (\"APT\") for the treatment of disorders with intractable neurologic symptoms including Autism Spectrum Disorder (\"ASD\").",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc7df62d-9042-47bd-b4b6-973adae7eba9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.171,
        "x": 0.033,
        "y": 0.088
      },
      "kind": "title",
      "text": "Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19e8785f-511a-4564-8819-fbee2d43a534",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "ac237db3-37b3-4fed-bea6-d3c1fea9b563",
      "evidence": "This slide provides an overview of the company and its focus, which is typical of an executive summary.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}